Basal Cell Carcinoma with a Relationship in Dermatology and Plastic Surgery

Abstract

Skin cancers known as basal cell carcinomas (BCCs) can cause significant localized damage. They represent the most prevalent kind of cancer in the West. A lifetime incidence of up to 39% is possible. The most prevalent risk factor is UV exposure. Most of these tumors are seen in the head and neck region. Even though BCCs are often benign, the great occurrence of these conditions implies that treating them adds significantly to the health service's already heavy workload. It's critical to have a solid grasp of your potential possibilities. A number of variables, such as the patient's age and comorbidities, the location and subtype of the lesion, and others, may affect management choices. Treatment choices for BCCs on the face may differ greatly from those for BCCs originating elsewhere due to the significance of a favorable cosmetic and curative result. Good randomized controlled studies comparing different treatment methods are hard to come by. While conventional excision has historically been the preferred course of treatment, there are now a number of other alternatives as well, including as radiation, cryosurgery, curettage and cautery, Mohs micrographic surgery, topical imiquimod, photodynamic therapy, and topical 5-fluorouracil. We go over and evaluate the research and literature supporting the current range of face BCC treatment options.